BACKGROUND: Increased IL-17A production has been associated with more severe asthma; however, the mechanisms whereby IL-17A can contribute to IL-13-driven pathology in asthmatic patients remain unclear. OBJECTIVE: We sought to gain mechanistic insight into how IL-17A can influence IL-13-driven responses. METHODS: The effect of IL-17A on IL-13-induced airway hyperresponsiveness, gene expression, mucus hypersecretion, and airway inflammation was assessed by using in vivo models of IL-13-induced lung pathology and in vitro culture of murine fibroblast cell lines and primary fibroblasts and human epithelial cell lines or primary human epithelial cells exposed to IL-13, IL-17A, or both. RESULTS: Compared with mice given intratracheal IL-13 alone, those exposed to IL-13 and IL-17A had augmented airway hyperresponsiveness, mucus production, airway inflammation, and IL-13-induced gene expression. In vitro, IL-17A enhanced IL-13-induced gene expression in asthma-relevant murine and human cells. In contrast to the exacerbating influence of IL-17A on IL-13-induced responses, coexposure to IL-13 inhibited IL-17A-driven antimicrobial gene expression in vivo and in vitro. Mechanistically, in both primary human and murine cells, the IL-17A-driven increase in IL-13-induced gene expression was associated with enhanced IL-13-driven signal transducer and activator of transcription 6 activation. CONCLUSIONS: Our data suggest that IL-17A contributes to asthma pathophysiology by increasing the capacity of IL-13 to activate intracellular signaling pathways, such as signal transducer and activator of transcription 6. These data represent the first mechanistic explanation of how IL-17A can directly contribute to the pathogenesis of IL-13-driven pathology.
BACKGROUND: Increased IL-17A production has been associated with more severe asthma; however, the mechanisms whereby IL-17A can contribute to IL-13-driven pathology in asthmatic patients remain unclear. OBJECTIVE: We sought to gain mechanistic insight into how IL-17A can influence IL-13-driven responses. METHODS: The effect of IL-17A on IL-13-induced airway hyperresponsiveness, gene expression, mucus hypersecretion, and airway inflammation was assessed by using in vivo models of IL-13-induced lung pathology and in vitro culture of murine fibroblast cell lines and primary fibroblasts and human epithelial cell lines or primary human epithelial cells exposed to IL-13, IL-17A, or both. RESULTS: Compared with mice given intratracheal IL-13 alone, those exposed to IL-13 and IL-17A had augmented airway hyperresponsiveness, mucus production, airway inflammation, and IL-13-induced gene expression. In vitro, IL-17A enhanced IL-13-induced gene expression in asthma-relevant murine and human cells. In contrast to the exacerbating influence of IL-17A on IL-13-induced responses, coexposure to IL-13 inhibited IL-17A-driven antimicrobial gene expression in vivo and in vitro. Mechanistically, in both primary human and murine cells, the IL-17A-driven increase in IL-13-induced gene expression was associated with enhanced IL-13-driven signal transducer and activator of transcription 6 activation. CONCLUSIONS: Our data suggest that IL-17A contributes to asthma pathophysiology by increasing the capacity of IL-13 to activate intracellular signaling pathways, such as signal transducer and activator of transcription 6. These data represent the first mechanistic explanation of how IL-17A can directly contribute to the pathogenesis of IL-13-driven pathology.
Authors: Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy Journal: Am J Respir Crit Care Med Date: 2009-05-29 Impact factor: 21.405
Authors: William W Busse; Stephen Holgate; Edward Kerwin; Yun Chon; Jingyuan Feng; Joseph Lin; Shao-Lee Lin Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Rhonda H Wilson; Gregory S Whitehead; Hideki Nakano; Meghan E Free; Jay K Kolls; Donald N Cook Journal: Am J Respir Crit Care Med Date: 2009-08-06 Impact factor: 21.405
Authors: M R Moon; A A Parikh; T A Pritts; J E Fischer; S Cottongim; C Szabo; A L Salzman; P O Hasselgren Journal: J Surg Res Date: 1999-03 Impact factor: 2.192
Authors: Yui-Hsi Wang; Kui Shin Voo; Bo Liu; Chun-Yu Chen; Burcin Uygungil; William Spoede; Jonathan A Bernstein; David P Huston; Yong-Jun Liu Journal: J Exp Med Date: 2010-10-04 Impact factor: 14.307
Authors: Monica G Chiaramonte; Margaret Mentink-Kane; Bruce A Jacobson; Allen W Cheever; Matthew J Whitters; Mary E P Goad; Anthony Wong; Mary Collins; Debra D Donaldson; Michael J Grusby; Thomas A Wynn Journal: J Exp Med Date: 2003-03-17 Impact factor: 14.307
Authors: Andrew R Patterson; Paige Bolcas; Kristin Lampe; Rachel Cantrell; Brandy Ruff; Ian Lewkowich; Simon P Hogan; Edith M Janssen; Jack Bleesing; Gurjit K Khurana Hershey; Kasper Hoebe Journal: J Allergy Clin Immunol Date: 2018-10-25 Impact factor: 10.793
Authors: Alejandro A Pezzulo; Rosarie A Tudas; Carley G Stewart; Luis G Vargas Buonfiglio; Brian D Lindsay; Peter J Taft; Nicholas D Gansemer; Joseph Zabner Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808
Authors: Shamus P Keeler; Eugene V Agapov; Michael E Hinojosa; Adam N Letvin; Kangyun Wu; Michael J Holtzman Journal: J Immunol Date: 2018-09-12 Impact factor: 5.422